Carna Biosciences Receivables

Carna Biosciences (CBIXF) currently reports a receivables of $120M as of June 2026. That compares with $72M in the prior-year period — up 61.8% year over year. Use the charts on this page to explore Carna Biosciences's receivables history and peer comparisons.

Carna Biosciences's receivables increased from $72M to $120M — a 61.8% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Carna Biosciences reported $120M in receivables as of June 2026. That compares with $72M in the prior-year period — up 61.8% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current receivables of $120M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Carna Biosciences, and consider following CBIXF for alerts when major investors trade the stock.

Carna Biosciences is classified in the Healthcare sector. On receivables, it currently shows $120M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing CBIXF with unrelated industries.